Zai Lab Acquires China Rights to GIST Treatment in $205 Million Deal
publication date: Jun 11, 2019
In a $205 million agreement, Zai Lab, a Shanghai-US biopharma, acquired Greater China rights to ripretinib, a treatment for GIST and other solid tumors developed by Deciphera Pharma of Boston. Ripretinib is an oral investigational KIT and PDGFRα kinase switch control inhibitor. Zai will pay $20 million upfront and be responsible for up to $185 million in potential development and commercial milestones, plus royalties on sales. Deciphera is assessing adding China sites to its ongoing global Phase III trial that compares ripretinib to sunitinib in second-line GIST patients. More details....
Stock Symbols: (NSDQ: ZLAB) (NSDQ: DCPH)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.